Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIDAXIS: HCQ or Lopinavir/ritonavir Prophylaxis in Healthcare Workers
NCT04328285Phase 3Terminated
- Sponsor
- CHU Saint-Etienne
- Start
- Apr 2020
- Primary completion
- May 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of hydroxychloroquine, lopinavir, ritonavir in coronavirus disease 2019 (COVID-19), sponsored by CHU Saint-Etienne. Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquinelopinavirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04328285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04328285.